{
  "source": "PA-Med-Nec-Zoryve.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2287-6\nProgram Prior Authorization/Medical Necessity\nMedication Zoryve® (roflumilast)\nP&T Approval Date 9/2022, 2/2023, 11/2023, 2/2024, 12/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nZoryve (roflumilast) 0.3% cream is a phosphodiesterase 4 inhibitor indicated for topical treatment\nof plaque psoriasis, including intertriginous areas, in patients 6 years of age and older. Zoryve\n(roflumilast) foam is indicated for the treatment of seborrheic dermatitis in adult and pediatric\npatients 9 years of age and older. Zoryve (roflumilast) 0.15% cream is indicated for the topical\ntreatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and\nolder.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Zoryve 0.3% cream will be approved based on all of the following criteria:\n(1) Diagnosis of plaque psoriasis\n-AND-\n(2) Minimum duration of a 4-week trial and failure, contraindication, or intolerance\nto one of the following topical therapies:\n(a) Corticosteroids (e.g., betamethasone, clobetasol, desonide)\n(b) Vitamin D analogs (e.g., calcitriol, calcipotriene)\n(c) Tazarotene\n(d) Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\n(e) Anthralin\n(f) Coal tar\n-AND-\n(3) Patient is not receiving Zoryve 0.3% cream in combination with a Targeted\nImmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib),\nOlumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zoryve 0.3% cream will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to therapy\n-AND",
    "rization will be issued for 12 months.\n2. Reauthorization\na. Zoryve 0.3% cream will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to therapy\n-AND-\n(2) Patient is not receiving Zoryve 0.3% cream in combination with a Targeted\nImmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib),\nOlumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nB. Seborrheic Dermatitis\n1. Initial Authorization\na. Zoryve foam will be approved based upon the following criterion:\n(1) Diagnosis of seborrheic dermatitis\n-AND-\n(2) Minimum duration of a 4-week trial and failure, contraindication, or intolerance\nto at least one of the following therapies:\n(a) Topical corticosteroids (e.g., betamethasone, hydrocortisone)\n(b) Topical, shampoo, or systemic antifungals (e.g., ketoconazole, ciclopirox,\nitraconazole)\n(c) Topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\n-AND-\n(3) Patient is not receiving Zoryve foam in combination with either of the following:\n(a) Biologic immunomodulator [e.g., Dupixent (dupilumab), Adbry\n(tralokinumab-ldrm)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services, Inc.\n2\na. Zoryve foam will be approved based upon the following criterion:\n(1) Documentation of positive clinical response to therapy\n-AND-\n(2) Patient is not receiving Zoryve foam in combination with either of the\nfollowing:\n(a) Biologic immunomodulator [e.g., Dupixent (dupilumab), Adbry\n(tralokinumab-ldrm)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/",
    "foam in combination with either of the\nfollowing:\n(a) Biologic immunomodulator [e.g., Dupixent (dupilumab), Adbry\n(tralokinumab-ldrm)]\n(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),\nOpzelura (topical ruxolitinib), Cibinqo (abrocitinib)]\nAuthorization will be issued for 12 months.\nC. Atopic Dermatitis\n1. Initial Authorization\na. Zoryve 0.15% cream will be approved based on all of the following criteria:\n(1) Diagnosis of mild to moderate atopic dermatitis\n-AND-\n(2) History of failure, contraindication, or intolerance to one of the following\ntherapeutic classes of topical therapies:\n(a) One of the following:\nFor mild atopic dermatitis: a topical corticosteroid [e.g., DesOwen\no\n(desonide), hydrocortisone] (any potency)\nFor moderate atopic dermatitis: a topical corticosteroid of at least a\no\nmedium- to high-potency (e.g., Elocon (mometasone furoate),\nSynalar (fluocinolone acetonide), Lidex (fluocinonide)]\n(b) One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic\n(tacrolimus)]*\n-AND-\n(3) Patient is not receiving Zoryve 0.15% cream in combination with a targeted\nimmunomodulator [e.g., Adbry (tralokinumab-ldrm), Cibinqo (abrocitinib),\nDupixent (dupilumab), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zoryve 0.15% cream will be approved based on both of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n3\n(1) Documentation of positive clinical response to therapy\n-AND-\n(2) Patient is not receiving Zoryve 0.15% cream in combination with a targeted\nimmunomodulator [e.g., Adbry (tralokinumab-ldrm), Cibinqo (abrocitinib),\nDupixent (dupilumab), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n* Elidel and Protopic/tacrolimus ointment require prior au",
    "nd the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n* Elidel and Protopic/tacrolimus ointment require prior authorization.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Zoryve cream [package insert]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; October\n2023.\n2. Elmets CA, Korman NJ, Farley Prater E, et al. Joint AAD-NPF guidelines of care for the\nmanagement and treatment of psoriasis with topical therapy and alternative medicine modalities\nfor psoriasis severity measures. J Am Acad Dermatol 2021;84:432-70.\n3. Zoryve foam [package insert]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; December\n2023.\nProgram Prior Authorization/Medical Necessity - Zoryve (tapinarof)\nChange Control\n9/2022 New program.\n2/2023 Revised trial and failure requirement from either two topical therapies\nor calcipotriene and betamethasone dipropionate to a trial and failure of\none topical therapy.\n11/2023 Updated not to be used in combination to Targeted Immunomodulators.\nSimplified reauthorization criteria to only require positive clinical\nresponse and not used in combination with other treatment medications.\nUpdated background to include patients 6 years of age and older.\nUpdated reference.\n2/2024 Added criteria for Zoryve foam for seborrheic dermatitis. Updated\nbackground and reference.\n12/2024 Added criteria for Zoryve 0.15% cream for atopic dermatitis. Updated\nplaque psoriasis criteria to specify 0.3% cream. Updated all\n© 2025 UnitedHealthcare Services, Inc.\n4\nauthorizations to 12 months. Removed prescriber requirements.\nUpdated background and reference.\n2/2025 Updated s",
    "is criteria to specify 0.3% cream. Updated all\n© 2025 UnitedHealthcare Services, Inc.\n4\nauthorizations to 12 months. Removed prescriber requirements.\nUpdated background and reference.\n2/2025 Updated step therapy requirements for atopic dermatitis to one agent\nand removed Eucrisa as a required step agent. Updated prior\nauthorization footnote.\n© 2025 UnitedHealthcare Services, Inc.\n5"
  ]
}